About CorInnova Incorporated

CorInnova Incorporated, founded in 2004 in College Station, Texas, is an early stage, medical device company that is engaged in the transfer of innovative, lifesaving technology from the laboratory of Dr. John C. Criscione at Texas A&M University. CorAmend™ is the flagship product under development and will be the first heart assist device in the market to be a promoter of good cardiac motion rather than a promoter of heart ejection or flow as with other devices. CorAmend™ eliminates aberrant motion of the heart where others induce it. CorAmend™ is designed to reverse the muscle damage and prevent a progression towards congestive heart failure over a period of time. CorInnova is presently performing preclinical testing and with funding from National Institute of Health & American Heart Association CorInnova is targeting the $5 billion global cardiovascular myocardial infarction device market segment.